Paper

Paper

Changelog Terms Privacy Issues Docs Support Foundation About

Ruxolitinib in treatment of severe coronavirus disease 20... | ResearchHub

Paper

Paper

Changelog Terms Privacy Issues Docs Support Foundation About

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial

0

Authors

Yang Cao•Jia Wei•Jianfeng Zhou

Published

May 26, 2020

Abstract

Accumulating evidence proposed Janus-associated kinase (JAK) inhibitors as therapeutic targets warranting rapid investigation.

Supporters

Support the authors with ResearchCoin

Journal

Journal of Allergy and Clinical Immunology

Topics

Cancer Oncology

Internal Medicine

Cancer Oncology

Internal Medicine

DOI

10.1016/j.jaci.2020.05.019

License

other-oa

Supporters

Support the authors with ResearchCoin

Journal

Journal of Allergy and Clinical Immunology

Topics

Cancer Oncology

Internal Medicine

Cancer Oncology

Internal Medicine

DOI

10.1016/j.jaci.2020.05.019

License

other-oa